Growth hormone receptor (GHR) and prolactin (PRL) receptor (PRLR) are homologous transmembrane class I cytokine receptors. In humans, GH interacts with GHR homodimers or PRLR homodimers and PRL interacts with only PRLR homodimers to promote signaling. In human breast cancer cells endogenously expressing both receptors, GHR and PRLR specifically coimmunoprecipitate. We previously devised a split luciferase complementation assay to study GHR and PRLR assemblages. In this technique, firefly luciferase is split into two fragments (N-and C-terminal fragments of the luciferase), each without enzyme activity and tethered to the tails of two receptors. The fragments restore luciferase activity when brought close to each other by the receptors. Real-time ligand-induced complementation changes reflect the arrangement of receptors and indicate that GHR/PRLR is arranged as a heteromultimer comprised of GHR-GHR homodimers and PRLR-PRLR homodimers. We now dissect determinants for GHR and PRLR homodimerization versus heteroassociation. GHR and PRLR have extracellular domains comprised of the ligand-binding N-terminal subdomain 1 and a membraneproximal subdomain 2 (S2), which fosters receptor-receptor contact. Based on previous studies of S2 versus the transmembrane domain (TMD) in GHR dimerization, we constructed GHR(PRLR S2 ), GHR(PRLR S2-TMD ), and GHR(PRLR TMD ), replacing GHR's S2 alone, S2 plus TMD, and TMD alone with PRLR's counterpart. We tested by complementation the ability of these chimeras and GHR or PRLR to homodimerize or heteroassociate. Comparing various combinations, we found GHR(PRLR S2 ) and GHR(PRLR S2-TMD ) behaved as PRLR, whereas GHR(PRLR TMD ) behaved as GHR regarding their dimerization partners. We conclude that S2 of GHR and PRLR, rather than their TMDs, determines their dimerization partner. (Endocrinology 158: 3235-3248, 2017) 
In the current study, we use the pattern of ligand-induced change in luciferase complementation as a signature to distinguish between dimeric versus multimeric arrangements of GHR and PRLR, asking which receptor domains determine their propensities to homodimerize versus heteromultimerize. We focus particularly on the roles of the S2 and TMD regions of each receptor, taking the approach of creating domainswapping chimeric versions of the two receptors to preserve overall topology. Our findings strongly suggest that formation of GHR-GHR or PRLR-PRLR homodimers is determined by the identity (GHR versus PRLR) of the S2 domain rather than by the identity of the TMD.
Materials and Methods

Materials
Common molecular biology reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. Restriction endonucleases were obtained from New England Biolabs (Beverly, MA). Cell culture medium, penicillin/streptomycin, and trypsin were purchased from Corning (Corning, NY). Fetal bovine serum was purchased from Atlanta Biologicals (Lawrenceville, GA). Gentamicin sulfate was purchased from RPI (Mt. Prospect, IL). Zeocin was purchased from Invitrogen (Carlsbad, CA). Recombinant human GH was provided by Eli Lilly (Indianapolis, IN). Recombinant human PRL was obtained from the National Hormone and Pituitary Program.
Antibodies
Polyclonal antibodies against GHR (anti-GHR cyt-AL47 , against the rabbit GHR intracellular domain) (18) , JAK2 (anti-JAK2 AL33 ) (19) , and PRLR (anti-PRLR cyt-AL84 , against the human PRLR intracellular domain) (20) were developed by our laboratory and have been reported. Polyclonal anti-pJAK2 antibody detecting phospho-JAK2 (Y 1007 and Y 1008 ) was purchased from EMD Millipore (Darmstadt, Germany). Monoclonal anti-pY (4G10) was purchased from Upstate Biotechnology (Lake Placid, NY). Polyclonal anti-luc (catalog no. G7451) was purchased from Promega (Madison, WI). Anti-PRLR ICD [PRL-R(H-300); catalog no. sc-20992] and antiglutathione S-transferase [GST(B-14); catalog no. sc-138] were purchased from Santa Cruz Biotechnology (Dallas, TX). Monoclonal anti-GHR ext-mAb and anti-GHR cyt-mAb were developed by our laboratory and described previously (21) (22) (23) (24) (25) . Monoclonal anti-PRLR ext-mAb was raised against a GST fusion containing the entire extracellular domain of the long form of the human PRLR. Clones were screened by enzyme-linked immunosorbent assay (positive for GST-human PRLR extracellular domain and negative for GST alone) and tested for immunoreactivity by immunoblotting and immunoprecipitation of human PRLR from T47D cells and by immunoblotting of GST fusion proteins containing either the subdomain 1 (S1) or S2 of PRLR extracellular domain (reported in this study).
Construction of the plasmids encoding GHR-PRLR chimeric receptors
The human GHR complementary DNA (cDNA) in pcDNA1 was a gift provided by R. Ross (University of Sheffield, Sheffield, UK). The human PRLR cDNA in pEF/V5/HIS was a gift provided by C. Clevenger (Virginia Commonwealth University, Richmond, VA). The full-length firefly luciferaseencoding plasmid has been described previously (16) . To construct the chimeric GHR(PRLR S2-TMD ), DNA fragments of GHR's S1, PRLR's S2, and TMD, and GHR's intracellular domain (ICD) were generated by polymerase chain reaction (PCR) with a 21-or 23-bp overlap sequence at the junctions between each adjacent fragment and then assembled by overlap extension PCR and cloned into pcDNA3.1(+)/zeo. GHR(PRLR S2 ) and GHR(PRLR TMD ) were assembled using the same strategy. For purposes of this study, PRLR S2 extends from the S1-S2 hinge region (IVQPDPP-a sequence shared by GHR and PRLR) to the end of ECD (spanning residues 100-210 of mature PRLR). The GHR cDNA sequence encoding S1-S2 hinge region IVQPDPP was used to construct each chimeric receptor containing PRLR S2. The cDNA of Nluc (encoding residues 1-398) or Cluc (encoding residues 394-550) with a flexible linker (AAAGSGGGGS) on the amino terminus of each fragment was created by PCR with the template being the full-length firefly luciferase cDNA. The Nluc/Cluc fragment was tethered downstream of human GHR, human PRLR, or chimeric GHR(PRLR S2-TMD ), GHR(PRLR S2 ), and GHR (PRLR TMD ) by overlap extension PCR with the stop codon of receptor cDNA being mutated to GGA (encoding a Gly), and subsequently cloned into pcDNA3.1(+)/zeo by two flanking restriction enzyme sites. ER-Cluc [estrogen receptor fragment (residues 130-398)-Cluc in the vector of pcDNA3.1/ puromycin] has been described previously (26) . The sequences of PCR primers are available upon request.
GST-S1 and GST-S2 are GST fusion proteins containing the S1 or S2 domain of human PRLR, respectively. cDNAs encoding PRLR S1 (residues 1-100) or PRLR S2 (residues 101-210) were inserted downstream of GST via EcoR1 and Xho1 sites in the pGEXT-4T plasmid backbone.
Cells, cell culture, and transfection T47D cells were purchased from American Type Culture Collection (Manassas, VA; ATCC HTB-133). g2A-JAK2 cells were generated by transfection of g2A cells (27) (gift of G. Stark, Cleveland Clinic, Cleveland, OH) with pcDNA3.1 (+)/zeo-JAK2 and carried in culture, as described previously (28, 29) . g2A-JAK2-GHR-Nluc cells were generated by cotransfection of g2A-JAK2 cells with pcDNA3.1(+)/zeo-GHR-Nluc and a hygromycin-encoding plasmid at a weight ratio as 20:1, followed by hygromycin selection and single clone amplification. g2A-JAK2-GHR(PRLR S2 )-Nluc cells were made in the same way. All double-stable clones, g2A-JAK2-GHR-Nluc/GHR-Cluc, g2A-JAK2-GHR-Nluc/ GHR(PRLR S2 )-Cluc, g2A-JAK2-GHR-Nluc/PRLR-Cluc, g2A-JAK2-GHR(PRLR S2 )-Nluc/PRLR-Cluc, and g2A-JAK2-PRLRNluc/PRLR-Cluc, were generated by cotransfection of plasmid-encoding receptor-Nluc, plasmid-encoding receptorCluc, and a hygromycin-encoding plasmid at a weight ratio as 9.5:9.5:1, followed by hygromycin selection and single clone amplification. All the stable clone cells were maintained in 500 mg/mL hygromycin-containing g2A-JAK2 cell medium. Transient expression of receptors was achieved by transfecting 0.3 pmol receptor-Cluc-encoding plasmid DNA per 6-cm 2 dish, unless otherwise indicated. Lipofectamine LTX Plus (Invitrogen) was used for transfection following the manufacturer's instructions.
Bioluminescence imaging
Transiently transfected cells or double-stable clone cells were seeded in 96-well black wall plates (3.6 3 10 4 cells/well). Six hours prior to experimentation, medium was replaced by serum-free medium. Then the medium was changed to imaging medium (175 ml/well; composed of phenol red-free Dulbecco's modified Eagle medium, 1 g/L glucose, 1 mg/mL D-luciferin, 25 mM HEPES, pH 7.5, 0.1% w/v bovine serum albumin) at room temperature for 10 minutes and at 37°C for 20 minutes. Baseline bioluminescence signal (photons/s/cm 2 /steradian) was collected at 37°C using an IVIS 100 system (Perkin Elmer, Waltham, MA; no filter; F-stop, 1; field of view, level B; Bin: 8; exposure time: 5 minutes). GH was added in a volume of 25 ml/ well to reach the final concentration of 500 ng/mL. Then the sequential bioluminescence imaging was commenced immediately thereafter with the same parameters at 5-minute intervals for 40 minutes. For the measurement of monoclonal antibodies' effect, anti-GHR ext-mAb , anti-PRLR ext-mAb , or anti-GHR cyt-mAb was added into the imaging medium with the final concentration at 40 mg/mL, incubated for 30 minutes, and measured for the bioluminescence with parameters described previously.
Protein extraction, immunoprecipitation, and immunoblotting
For immunoprecipitation, T47D cells were serum starved overnight, treated with or without 500 ng/mL PRL at 37°C for 10 min, washed with ice-cold phosphate-buffered saline with Na 3 VO 4 (400 mM), a phosphatase inhibitor, and lysed. Cell lysates were immunoprecipitated with anti-PRLR ext-mAb or anti-PRLR ICD . Elutes were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and immunoblotted with indicated antibodies.
For immunoblotting, cells were plated in 96-well plates for bioluminescence imaging and 6-well plates (5.4 3 10 5 cells/ well) for biochemical data. The cells in 6-well plates were serum starved for 6 hours, treated with or without 500 ng/mL GH at 37°C for 10 minutes, terminated from the stimulation by sitting the plates on ice, and washed with ice-cold phosphate-buffered saline with Na 3 VO 4 (400 mM), a phosphatase inhibitor. Detergent extraction, electrophoresis, and immunoblotting of the cultured cells were performed, as previously described (22, 30) .
GST-S1 and GST-S2 were expressed in Escherichia coli (BL-21) and purified, as previously described (31) .
Statistical analysis and figure preparation
For bioluminescence complementation, each experimental condition was assessed in triplicate wells of 96-well plate. Each well was defined as a region of interest that generates a basal bioluminescence value expressed as total flux 6 standard error (SE; photons per second). The percentage change of complementation signal was calculated by dividing the total flux value from vehicle-treated or GH-treated wells by the baseline total flux value from this same set of wells and subtracting the vehicle-induced change from the GH-induced change. Data are expressed as mean 6 SE of GH-induced signal change as a percentage above baseline signal (n = 3). The split luciferase complementation data shown are in all instances representative of at least three experiments. For the bar graphs of monoclonal antibodies' effects, bioluminescence was detected in triplicate in a 96-well plate format and normalized to the mean value from the vehicle buffer-incubated wells. Each bar represents data from three independent experiments and is displayed as mean of the fold change 6 SE. Two sample t tests with equal variance and pooled SE were used for statistical analysis comparing antibody-treated cells with vehicle-treated cells. P , 0.05 was considered as significant. In figures of some immunoblots, irrelevant intervening lanes from original immunoblots have been cropped for clarity of presentation. In these cases, a space is maintained where intervening lanes were cropped. In all cases, only data from the same original blots are incorporated in figures with consistent brightness/contrast adjustment made across each blot.
Results
Domain-swapped GHR(PRLR) chimeric receptors and their luc hybrids are expressed at the cell surface and respond to ligand stimulation
To dissect the roles of the ECD S2 and the TMD regions of GHR and PRLR in allowing receptor dimers to form, we took a domain-swapping approach to best preserve overall receptor topology and thus functional integrity. Specifically, we swapped either S2 and TMD together, S2 alone, or TMD alone of human PRLR to replace the same domains of human GHR into the backbone of the GHR. Figure 1 graphically represents the structures of GHR (gray) or PRLR (orange) fused at the receptor ICD C terminus to either Nluc or Cluc via a flexible 10-residue linker (AAAGSGGGGS), as previously reported (6, 13) . Also graphically shown in Fig. 1(a) are the structures of three receptor-luc fusions in which the receptor portion is a chimera in which GHR domains are replaced by PRLR S2 and TMD, PRLR S2, or PRLR TMD; the receptor chimera components are, respectively, named GHR(PRLR S2-TMD ), GHR(PRLR S2 ), and GHR(PRLR TMD ).
To explore the structural and functional integrity of these chimeras and fusion proteins, we transiently transfected each into the GHR-and PRLR-deficient human fibrosarcoma cell line, g2A-JAK2 (28, 29), which amply expresses JAK2, a cytoplasmic tyrosine kinase that couples to both GHR and PRLR (31) (32) (33) (34) (35) . As anticipated, expression of GHR and PRLR was easily detected by immunoblotting of cell extracts by our antisera specific for the ICDs of each protein, and acute GH treatment resulted in phosphorylation of JAK2 for each receptor [ Fig , and GHR(PRLR TMD ) and its Nluc and Cluc hybrids yielded specifically detected (GHR ICD-reactive) proteins of expected M r , and each allowed acute GH-induced JAK2 tyrosine phosphorylation. As human GH binds both human GHR and PRLR (36) (37) (38) and GH binds GHR almost exclusively via the S1 domain (39), we interpret the data in Fig. 1 to indicate that each chimeric receptor was expressed at the cell surface, bound GH, and transduced GH binding to activation of JAK2. Furthermore, these trafficking, binding, and signaling capacities were retained for each chimera when fused to either Nluc or Cluc.
Basal and ligand-induced complementation of GHR-Nluc with receptor-Clucs and chimera-Clucs
To compare the dimer/multimer arrangements of chimeric receptors with wild-type receptors, we transiently transfected each chimera-Cluc versus GHR-Cluc or PRLR-Cluc into a version of g2A-JAK2 cells that stably expresses GHR-Nluc [so-called g2A-JAK2-GHRNluc cells (6) cells]. We first examined the degree to which reconstitution of luciferase activity (complementation) was allowed between the Cluc-containing receptors and GHR-Nluc [ Fig. 2(a) ]. As anticipated from our previous studies (6, 13) , expression of either GHR-Cluc or PRLR-Cluc yielded complementation when expressed in g2A-JAK2-GHR-Nluc. The specificity of this complementation was validated by comparison with transfection of either vector only or a fragment of estrogen receptor fused to Cluc (ER-Cluc) (26) , which is largely expressed in the cytosol and serves as a negative control. Notably, expression of each of the three receptor chimera-Cluc hybrids-GHR(PRLR S2-TMD )-Cluc, GHR(PRLR S2 )-Cluc, or GHR(PRLR TMD )-Clucyielded basal complementation [ Fig. 2(a) ]. Expression of the relevant transfected proteins and of the endogenous GHR-Cluc was verified by immunoblotting of cell extracts [ Fig. 2(b) ]. In principle, the three chimeraCluc hybrids and GHR-Cluc should be equally recognized by anti-GHR cyt-AL47 , allowing for comparison by immunoblotting of the relative abundance of these four constructs. Notably, the hierarchy of their protein levels accurately reflected the hierarchy of their basal bioluminescence in g2A-JAK2-GHR-Nluc cells. For example, GHR(PRLR TMD )-Cluc had both the lowest abundance among these four constructs [ Fig. 2(b) ] and the lowest basal complementation with GHR-Nluc [ Fig. 2(a) ]. Although transient transfection resulted in varied expression levels in these three chimera-Cluc hybrids, their basal complementation signals were comparable to that observed with transfection of GHRCluc or PRLR-Cluc and dramatically greater than with ER-Cluc transfection. Thus, like GHR-Cluc and PRLR-Cluc, chimeras with S2 and/or TMD from PRLR replacing those domains from GHR, when fused to Cluc, were similarly capable of complementation with GHR-Nluc.
We next tested the effects of treatment with GH on the complementation of each receptor-Cluc hybrid with GHR-Nluc [ Fig. 2(c) ]. Bioluminescence was measured serially at 5-minute intervals over 40 minutes after addition of GH to monitor changes in basal complementation that are caused by GH, and this GH-induced change was presented as the percentage over baseline signal through time. In g2A-JAK2-GHR-Nluc cells transfected with GHR-Cluc, GH induced an acute augmentation of bioluminescence that began to decline after 5 minutes, approaching baseline after ;30 to 40 minutes. In contrast, in g2A-JAK2-GHR-Nluc cells transfected with PRLR-Cluc, GH induced a steady decline in bioluminescence over ;30 to 40 minutes. These data on GHR-Nluc/GHR-Cluc and GHR-Nluc/PRLR-Cluc complementation were consistent with our previous findings (6, 13) and highlight the different GH-induced signature patterns for what we interpret are GHR-GHR homodimers versus GHR-GHR/PRLR-PRLR heteromultimers (which are comprised of GHR-GHR dimers and PRLR-PRLR dimers) (13) . Interestingly, the GHinduced tracing from g2A-JAK2-GHR-Nluc cells transfected with GHR(PRLR TMD )-Cluc mimicked that observed with GHR-Cluc transfection-acute augmentation followed by decline toward baseline-, suggesting a similar receptor dimer arrangement of GHR-Nluc/GHR (PRLR TMD )-Cluc as that of GHR-Nluc/GHR-Cluc. In contrast, transfection of chimera-Cluc hybrids that substitute either the PRLR S2 alone [GHR(PRLR S2 )-Cluc] or both the PRLR S2 and PRLR TMD [GHR(PRLR S2-TMD )-Cluc] into g2A-JAK2-GHR-Nluc cells yielded GH-induced tracings of the same pattern as that observed with PRLR-Cluc transfection-a steady decline from baseline. This suggests that the arrangements of GHR-Nluc/GHR(PRLR S2 )-Cluc and GHR-Nluc/ GHR(PRLR S2-TMD )-Cluc were similar to that observed for GHR-Nluc/PRLR-Cluc, and that these receptors were arranged as heteromultimers made up of homodimers, rather than as heterodimers per se. These data are consistent with the notion that, among GHRs and PRLRs, the S2 domain, rather than the TMD, is necessary for formation of dimers and that receptors containing nonhomologous S2 domains do not dimerize, but can form multimeric assemblages consisting of dimers, each partner of which bears homologous S2 domains.
Basal and ligand-induced complementation of GHR(PRLR S2 )-Nluc with receptor-Clucs and chimera-Clucs
The data in Fig. 2 suggest that dimerization is conferred by the presence of GHR S2 in both receptor dimer partners. To pursue further the reciprocal requirement for PRLR S2 in dimer formation, we created a clone, g2A-JAK2-GHR(PRLR S2 )-Nluc, in which GHR(PRLR S2 )-Nluc is stably expressed in g2A-JAK2 cells. Consistent with its behavior in transiently transfected cells [ Fig. 1  (c) ], this chimera-Nluc, when stably expressed, reached the cell surface, bound GH, and allowed JAK2 activation and phosphorylation of both the receptor and JAK2 [ Fig. 3(a) ]. To test complementation, we transiently transfected g2A-JAK2-GHR(PRLR S2 )-Nluc cells with GHR-Cluc, PRLR-Cluc, or GHR(PRLR S2 )-Cluc, or, as negative controls, ER-Cluc or empty vector. Each transiently transfected protein, as well as endogenously stably expressed GHR(PRLR S2 )-Nluc, was specifically detected in cell extracts by immunoblotting with either anti-GHR or anti-luc [ Fig. 3(b) and 3(c) ]. Furthermore, transiently transfected GHR-Cluc, PRLR-Cluc, and GHR(PRLR S2 )-Cluc, but not ER-Cluc or vector, each complemented the stably expressed GHR(PRLR S2 )-Nluc [ Fig. 3(d) ], indicating that, as expected, each of the three Cluc-containing hybrids specifically interacts with GHR(PRLR S2 )-Nluc.
The effect of ligand engagement was tested by tracking changes in complementation in response to GH treatment [ Fig. 3(e) ]. Both GHR(PRLR S2 )-Cluc and PRLRCluc displayed GH-induced augmentation of basal complementation with GHR(PRLR S2 )-Nluc. In contrast, GH triggered a decline in basal bioluminescence signal in g2A-JAK2-GHR(PRLR S2 )-Nluc cells transiently expressing GHR-Cluc [ Fig. 3(e) ]. This is consistent with the GH-induced bioluminescence profile observed with coexpression of GHR-Nluc and GHR(PRLR S2 )-Cluc [ Fig. 2(c)] ; thus, the same findings applied independent of whether Nluc or Cluc was fused to GHR or GHR (PRLR S2 ) or vice versa. Again, GHR(PRLR S2 ) behaved more like PRLR than like GHR in both formats. The data suggest that the PRLR S2 domain is sufficient to drive its PRLR-like behavior in terms of complementation with GHR, PRLR, or GHR-PRLR chimeras, forming dimers with receptors containing another PRLR S2 domain and heteromultimers with receptors containing a GHR S2 domain. If the identity of S2 principally determines the dimerization partner, we would predict that GHR (PRLR S2-TMD )-Cluc, but not GHR(PRLR TMD )-Cluc, will dimerize with GHR(PRLR S2 )-Nluc. To test these predictions, g2A-JAK2-GHR(PRLR S2 )-Nluc cells were transiently transfected with either GHR(PRLR S2-TMD )-Cluc or GHR(PRLR TMD )-Cluc or with controls including GHR-Cluc, PRLR-Cluc, ER-Cluc, and empty vector (Fig. 4) . We verified expression of each of the relevant proteins by immunoblotting [ Fig. 4(a) ] and, as anticipated, detected robust basal complementation from GHR(PRLR S2 )-Nluc with GHR(PRLR S2-TMD )-Cluc, or GHR(PRLR TMD )-Cluc, GHR-Cluc, and PRLRCluc, but not with ER-Cluc [ Fig. 4(b) ]. Note that in this transient transfection, GHR(PRLR TMD )-Cluc again displayed lower protein abundance [ Fig. 4(a) ] and thus a lower basal bioluminescence level [ Fig. 4(b) ] compared with GHR(PRLR S2-TMD )-Cluc and GHR-Cluc. However, the complementation level was still robust and specific compared with ER-Cluc transfection. As expected, GH treatment of g2A-JAK2-GHR(PRLR S2 )-Nluc cells augmented complementation when PRLR-Cluc was expressed and lessened complementation when GHR-Cluc was expressed [ Fig. 4(c) ]. In g2A-JAK2-GHR(PRLR S2 )-Nluc cells expressing GHR(PRLR S2-TMD )-Cluc (harboring the PRLR S2 domain), GH augmented complementation, mimicking the results with PRLR-Cluc. However, in g2A-JAK2-GHR(PRLR S2 )-Nluc cells expressing GHR (PRLR TMD )-Cluc (harboring the GHR S2 domain and the PRLR TMD), GH triggered reduced complementation in a pattern indistinguishable from that seen when GHR-Cluc was expressed. Collectively, the data in Fig. 4 emphasize that S2, and not the TMD, is most likely necessary and sufficient to determine the dimerization partner between GHR and PRLR.
Effects of anti-GHR and anti-PRLR ECD monoclonal antibodies on receptor-luc and chimera-luc complementation
Anti-GHR ext-mAb is an inhibitory monoclonal antibody (mAb) that interacts largely with the S2 of GHR's ECD [ Fig. 5(a)] (22, 23) . Pretreatment with anti-GHR ext-mAb inhibits subsequent GH-induced activation of GHR dimers in vitro and in vivo with little effect on GH binding; rather, this mAb appears to prevent GH-induced GHR conformational changes required for signaling (22, 23) . Using our split luciferase complementation assay, we previously found that anti-GHR ext-mAb treatment alone Figure 5 . Effect of anti-GHR ext-mAb suggests lack of dimerization between GHR and GHR(PRLR S2 ). (a) Diagram of the GHR domains that interact with anti-GHR ext-mAb , anti-GHR cyt-mAb , and GH. (b) Three double-stable clones with GHR-Nluc but distinct receptor-Clucs. g2A-JAK2-GHR-Nluc/ GHR-Cluc, g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc, and g2A-JAK2-GHR-Nluc/PRLR-Cluc cells were analyzed by immunoblotting with anti-GHR and anti-PRLR. Brackets on the left side of each lane indicate the position of GHR-Nluc, which is comprised of both the upper mature (less distinct) and lower precursor (sharper) bands. Braces on the right of lanes 1 and 2 indicate the positions of GHR-Cluc and GHR(PRLR S2 )-Cluc, each comprised of both the mature and precursor bands. Note that the GHR-Nluc precursor and the GHR-Cluc mature form overlap in lane 1 to produce a more intense combined band. (c) GH-induced complementation change in three GHR-Nluc-expressing double-stable clones. g2A-JAK2-GHR-Nluc/GHR-Cluc, g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc, and g2A-JAK2-GHR-Nluc/PRLR-Cluc cells were measured for basal bioluminescence in triplicate in a 96-well plate format. GH was added, and bioluminescence was again serially detected at 5-minute intervals over 40 minutes. Data are displayed as mean 6 SE of GH-induced signal as a percentage above baseline signal (n = 3 per condition). (d) Anti-GHR ext-mAb enhances basal complementation of GHR-Nluc/GHR-Cluc, but not of GHR-Nluc/GHR(PRLR S2 )-Cluc or GHR-Nluc/PRLR-Cluc. g2A-JAK2-GHR-Nluc/GHR-Cluc, g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc, and g2A-JAK2-GHR-Nluc/PRLR-Cluc cells were incubated with vehicle buffer, anti-GHR ext-mAb , or anti-GHR cyt-mAb for 30 minutes. Bioluminescence was detected in triplicate in a 96-well plate format and normalized to the mean value from the vehicle buffer-incubated cells. Each bar represents data from three independent experiments and is displayed as mean of the fold change 6 SE. *P , 0.05 when compared with respective vehicle treatment in each cell line.
specifically enhanced basal complementation observed with coexpression of GHR-Nluc with GHR-Cluc without triggering receptor activation (6) . This was interpreted as anti-GHR ext-mAb introducing into GHR dimers a nonproductive conformational change (reflected in enhanced complementation signal) that prevents the GH-induced receptor conformational changes required for activation, and we took this mAb-induced receptor conformational change as a potential signature of receptor dimers.
To test this further, we sought to compare how anti-GHR ext-mAb would affect complementation between GHR-Nluc and either GHR-Cluc, GHR(PRLR S2 )-Cluc, or PRLR-Cluc. To allow adequate comparison, we created three doubly-transfected clonal cell lines that each stably expressed GHR-Nluc and one of the Cluc hybrids-these cell lines were designated g2A-JAK2-GHRNluc/GHR-Cluc, g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc, and g2A-JAK2-GHR-Nluc/PRLR-Cluc to connote that each stably expressed two different receptor-luc or chimera-luc hybrids. Immunoblotting with anti-GHR and anti-PRLR intracellular domain antisera verified expression of each protein in the three clones [ Fig. 5(b) ]. Each doublestable cell line displayed robust basal complementation (data not shown), and their patterns of complementation change in response to GH [ Fig. 5(c) ] conformed to those observed [ Fig. 2(c) ] when g2A-JAK2-GHR-Nluc was transiently transfected with each of the Cluc-containing hybrids. GH induced augmentation of complementation in g2A-JAK2-GHR-Nluc/GHR-Cluc (harboring GHR homodimers) and decline of complementation in g2A-JAK2-GHR-Nluc/PRLR-Cluc (harboring GHR-GHR/ PRLR-PRLR heteromultimers). Again, GHR(PRLR S2 )-Cluc behaved like PRLR-Cluc, but not GHR-Cluc, in that GH treatment of g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc (harboring heteromultimers) caused decline of complementation nearly the same as that seen for g2A-JAK2-GHR-Nluc/PRLR-Cluc. To evaluate their mAb response, bioluminescence of each of the three clones was monitored after treatment with either vehicle, a control antibody (anti-GHR cyt-mAb ; directed at the GHR intracellular domain), or anti-GHR ext-mAb [ Fig. 5(d) ]. As anticipated based on previous findings with transiently transfected cells (6), anti-GHR ext-mAb specifically augmented complementation in g2A-JAK2-GHR-Nluc/ GHR-Cluc cells, consistent with this mAb response being a signature of GHR-GHR dimers. Furthermore, anti-GHR ext-mAb failed to elicit a change in bioluminescence for either g2A-JAK2-GHR-Nluc/PRLR-Cluc or g2A-JAK2-GHR-Nluc/GHR(PRLR S2 )-Cluc.
We recently raised a mouse mAb against the PRLR ECD [ Fig. 6(a) ], anti-PRLR ext-mAb. This mAb recognizes native human PRLR, as demonstrated by immunoprecipitation of both total and PRL-induced phosphorylated receptor in T47D breast cancer cells [ Fig. 6(b) ]. Anti-PRLR ext-mAb recognizes S2 (and not S1) of PRLR, as demonstrated by immunoblotting of GST fusion proteins incorporating either S1 or S2 [ Fig. 6(c) ]. Analogous to the experiments in Fig. 5 with anti-GHR ext-mAb , we sought to test effects of anti-PRLR ext-mAb on complementation of receptor pairs in three double-stable transfectant cell lines, each harboring PRLR-Cluc, namely: g2A-JAK2-GHR-Nluc/PRLR-Cluc, g2A-JAK2-GHR(PRLR S2 )-Nluc/PRLR-Cluc, and g2A-JAK2-PRLR-Nluc/PRLR-Cluc. Immunoblotting verified expression of each protein in the three clones [ Fig. 6(d) ]. When stimulated with GH [ Fig. 6(e) ], bioluminescence in g2A-JAK2-PRLR-Nluc/PRLR-Cluc was increased [consistent with our previous findings (13) Fig. 6(f) ]. Yet, anti-PRLR ext-mAb had no effect on complementation when PRLR-Nluc was replaced by GHR-Nluc (g2A-JAK2-GHR-Nluc/PRLRCluc cells). However, complementation was strongly increased by anti-PRLR ext-mAb treatment of g2A-JAK2-GHR(PRLR S2 )-Nluc/PRLR-Cluc cells (in which both receptors harbor the S2 domain from PRLR). The data in Fig. 6 are again consistent with the notion that both PRLR-Nluc and GHR(PRLR S2 )-Nluc, but not GHRNluc, can dimerize with PRLR-Cluc. Of note, two clones (those harboring GHR-Nluc/PRLR-Cluc or PRLR-Nluc/PRLR-Cluc) had sister clones whose responses to anti-GHR ext-mAb and/or anti-PRLR ext-mAb were consistent with the clones included in Figs. 5 and 6 (data not shown). Furthermore, as to the stable clones GHR-Nluc/ GHR(PRLR S2 )-Cluc and GHR(PRLR S2 )-Nluc/PRLRCluc, the results of mAb-induced changes were also observed in transient transfections (data not shown). These findings bolster those observed with the stable clones used in Figs. 5 and 6. Collectively, using the split luciferase complementation assay to analyze effects of treatment with mAbs (Figs. 5 and 6 ), or GH (Figs. 2-4) , we revealed that the chimeric receptor GHR(PRLR S2 ) has a PRLR-like, not GHR-like, behavior. We accordingly conclude that the S2 of GHR or PRLR is both necessary and sufficient to determine dimerization partner of these two receptors. Dimerization results when two receptor monomers share the same S2 domain.
Discussion
Our previous studies led us to conclude that GHRs and PRLRs can associate and form multimers composed of GHR-GHR homodimers and PRLR-PRLR homodimers, with each homodimer being independently activated by its ligand (13, 17) . In the current study, we extended our analysis by adopting a domain-swapping approach to create GHR-PRLR chimeric receptors. We investigated their response to GH and anti-GHR or anti-PRLR mAbs in the split luciferase complementation assay and found that S2 itself is both necessary and sufficient to dictate the character of the chimeric receptor with regard to whether it forms dimers. When the chimeric receptor harbors the S2 from GHR, it behaves like GHR in terms of forming dimers with another receptor that harbors the GHR S2. When the chimeric receptor harbors the S2 from PRLR, it behaves like PRLR in that it forms dimers with another receptor that harbors the PRLR S2. Unlike S2, the origin of TMD did not alter the overall S2-dictated GHR-like or PRLR-like behavior of a particular chimeric receptor. Thus, we conclude that in a GHR-GHR/PRLR-PRLR multimeric complex, S2, and not the TMD, determines the dimerization partner of each receptor.
Our findings are consistent with our previous report that suggested an important role for S2, and not for the TMD, in GHR predimerization (2) . In that study, we assessed the capacity for GHRs to associate using a (e) GH-induced complementation change in three PRLR-Cluc-expressing double-stable clones. g2A-JAK2-GHR-Nluc/PRLR-Cluc, g2A-JAK2-GHR(PRLR S2 )-Nluc/PRLR-Cluc, and g2A-JAK2-PRLR-Nluc/PRLR-Cluc cells were measured for basal bioluminescence in triplicate in a 96-well plate format. GH was added, and bioluminescence was again serially detected at 5-minute intervals over 40 minutes. Data are displayed as mean 6 SE of GH-induced signal as a percentage above baseline signal (n = 3 per condition). (f) Anti-PRLR ext-mAb enhances basal complementation of GHR(PRLR S2 )-Nluc/PRLR-Cluc or PRLR-Nluc/PRLR-Cluc, but not of GHR-Nluc/PRLR-Cluc. g2A-JAK2-GHR-Nluc/PRLR-Cluc, g2A-JAK2-GHR(PRLR S2 )-Nluc/PRLR-Cluc, and g2A-JAK2-PRLR-Nluc/PRLR-Cluc cells were incubated with vehicle buffer, anti-PRLR ext-mAb , or anti-GHR cyt-mAb for 30 minutes. Bioluminescence was detected in triplicate in a 96-well plate format and normalized to the mean value from the vehicle buffer-incubated cells. Each bar represents data from three independent experiments and is displayed as mean of the fold change 6 SE. *P , 0.05 when compared with respective vehicle treatment in each cell line. coimmunoprecipitation assay. When the TMD of GHR was replaced with a heterologous TMD [that of the lowdensity lipoprotein receptor (LDLR)], the resulting chimeric receptor-GHR LDLR -was equally able as wildtype GHR to coimmunoprecipitate with a GHR truncated of its ICD. In contrast, a GHR mutant with a disrupted S2 region was markedly less able to coimmunoprecipitate with the truncated GHR. However, other studies that used forster resonance energy transfer (FRET) have implicated a more prominent role for the TMD in GHR dimer formation (3), in that FRET signals were detectable in either ECD-deleted or ICD-deleted GHR dimers. Collectively, these findings, in concert with those reported in this work, may suggest roles for both the ECD S2 and TMD regions in facilitating GHR dimerization with S2 required for stabilizing the mature cell surface GHR dimer and the TMD contributing to predimer formation at early stages in the secretory pathway, as previously suggested (2) .
As noted previously (6), our findings of GH-induced enhancement of luciferase complementation in the setting of GHR dimers [or expression of PRLR dimers (13) or dimers that contain the same S2 region (the current study)] are at odds with some conclusions drawn from some (3, 5), but not other (4), studies using FRET/bioluminescence resonance energy transfer (BRET) methods.
We note that the Waters group measured the FRET/ BRET signal of activated state of GHR dimers at only one time point following GH treatment or in a constitutively activated GHR mutant and concluded that GH causes a separation of the proximal ICD of GHR (and therefore lessening of the FRET/BRET signal) as part of the activation process (5) . In contrast, the Gertler group (4) measured the time course of GH-induced FRET signal changes in intact cells and found instead a transient GHinduced augmentation of signal, more similar to our luciferase complementation findings, which were obtained serially in the setting of GH stimulation of native (or subdomain-swapped and not constitutively active) receptors in intact living cells. As previously discussed, we cannot yet fully explain reasons for the apparently disparate FRET/BRET findings in the literature or between some of those findings and our luciferase complementation findings. Further biophysical studies may be helpful in this regard. In any case, our internally consistent complementation findings provided a useful signature that distinguishes between dimeric versus multimeric arrangements of GHR and PRLR and allowed further dissection of determinants for these arrangements.
Like GHR, ligand-independent (pre)dimerization of PRLR and its isoforms has been demonstrated (9, 12, 40) and neither ECD deletion nor ICD deletion of PRLR completely eliminated receptor predimerization (12) . Also like GHR, the crystal structure of PRL with PRLR ECD revealed a 1:2 PRL:PRLR complex, and the interface between PRLR dimers encompassed the S2-S2 interaction (11) . Again, our current data with the luciferase complementation assay and chimerized GHR/ PRLR-luc fusions are consistent with a role for the S2 region in ligand-independent PRLR dimerization, in addition to its being a locus of PRLR-PRLR interaction in the setting of ligand binding.
Homomultimeric complexes, including GHRs alone or PRLRs alone, have been suggested by use of the biochemical technique of blue native gel electrophoresis of cell extracts (9, 41) . Existence of such GHR or PRLR homomultimers in the intact cellular context has yet to be demonstrated by microscopy. However, emerging data suggest such assemblages for other cell surface proteins and signaling receptors (e.g., epidermal growth factor receptor) that form higher-order oligomers and/or nanoclusters in the plasma membrane and that these complexes are not likely to be artifacts of overexpression (42) (43) (44) (45) .
Our previous data (13) and that presented in this work suggest that GHR-PRLR heteromultimeric complexes also exist, but that the dimeric components of these multimers are limited to GHR-GHR and PRLR-PRLR homodimers, rather than inclusive of GHR-PRLR heterodimers. Inherent to this model is that determinants of dimerization versus multimerization may differ and be of different specificity. For example, one could envision strict specificity for dimer formation (GHR only with GHR; PRLR only with PRLR, for example), but more flexibility in terms of other receptors (perhaps also as dimers) that might be included in multimeric complexes with GHR-GHR and PRLR-PRLR dimers under some circumstances. Such arrangements could confer varying signaling outcomes and/or kinetics for GH and PRL stimulation, depending on relative receptor expression levels and/or local cellular or tissue situations. Future studies will focus on discerning more finely the determinants for dimerization and comparing them with those for multimer formation, as well as uncovering biologically relevant consequences of such arrangements.
